Related references
Note: Only part of the references are listed.A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model
Hedwig M. Blommestein et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
A systematic review of cost-effectiveness analyses of complex wound interventions reveals optimal treatments for specific wound types
Andrea C. Tricco et al.
BMC MEDICINE (2015)
Decision-analytic modeling studies: An overview for clinicians using multiple myeloma as an example
U. Rochau et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
A systematic review of economic evaluations assessing interventions aimed at preventing or treating pressure ulcers
Simon J. Palfreyman et al.
INTERNATIONAL JOURNAL OF NURSING STUDIES (2015)
The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence
Gisela Hostenkamp et al.
SOCIAL SCIENCE & MEDICINE (2015)
A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis
Mickael Hiligsmann et al.
PHARMACOECONOMICS (2015)
Updating Cost-Effectiveness - The Curious Resilience of the $50,000-per-QALY Threshold
Peter J. Neumann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Cost-Effectiveness of Initial Treatment of Multiple Myeloma in the U.S. With Bortezomib Plus Melphalan and Prednisone Versus Thalidomide Plus Melphalan and Prednisone or Lenalidomide Plus Melphalan and Prednisone With Continuous Lenalidomide Maintenance Treatment
Louis P. Garrison et al.
ONCOLOGIST (2013)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
Don Husereau et al.
VALUE IN HEALTH (2013)
Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece
Vassilis Fragoulakis et al.
Cancer Management and Research (2013)
Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales
Ruth E. Brown et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2013)
Model Parameter Estimation and Uncertainty Analysis: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6
Andrew H. Briggs et al.
MEDICAL DECISION MAKING (2012)
Critical review of economic evaluations in multiple myeloma: An overview of the economic evidence and quality of the methodology
Jennifer G. Gaultney et al.
EUROPEAN JOURNAL OF CANCER (2011)
The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation
J. Picot et al.
HEALTH TECHNOLOGY ASSESSMENT (2011)
Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2
David C. Hoaglin et al.
VALUE IN HEALTH (2011)
Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1
Jeroen P. Jansen et al.
VALUE IN HEALTH (2011)
Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib
Jörgen Möller et al.
JOURNAL OF MEDICAL ECONOMICS (2011)
The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective
John Hornberger et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Modeling in pharmacoeconomic studies: Funding sources and outcomes
Livio Garattini et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2010)
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report-Part I
Joel W. Hay et al.
VALUE IN HEALTH (2010)
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
R. A. Kyle et al.
LEUKEMIA (2009)
Interpreting the Results of Cost-Effectiveness Studies
David J. Cohen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
Donna M. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Extended follow-up of a phase 3 trial in relapsed multiple myeloma:: final time-to-event results of the APEX trial
Paul G. Richardson et al.
BLOOD (2007)
Bias in published cost effectiveness studies: systematic review
CM Bell et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
